Association Between the CYP2B6 Polymorphisms and Nonnucleoside Reverse Transcriptase Inhibitors Drug-induced Liver Injury: a Systematic Review and Meta-analysis

Overview

Journal Sci Rep

Specialty Science

Date 2024 Nov 28

PMID 39604537

Authors

Noppadol Chanhom

Janjira Sonjan

Jarupat Inchai

Wanvisa Udomsinprasert

Usa Chaikledkaew

Supharat Suvichapanich

Surakameth Mahasirimongkol

Jiraphun Jittikoon

Affiliations

Soon will be listed here.

Abstract

Nevirapine (NVP) and Efavirenz (EFV) can cause antiretroviral drug-induced liver injury (ARVDILI). The objectives of this study were to summarize and analyze existing data on pharmacogenomics associated with nonnucleoside reverse transcriptase inhibitors drug-induced liver injury using systematic review and meta-analysis. This study systematically searched the relevant studies regarding pharmacogenes related to ARVDILI from online databases. Genes-encoding proteins were further analyzed using the STRING program to determine the protein-protein interactions (PPI). CYP2B6 polymorphisms were further meta-analyzed. Seventeen genes have been shown to be significantly associated with ARVDILI. Illustration from STRING analysis, CYP2B6, CYP1A1, and CYP2D6 enzymes have been recognized as central proteins linked to all other analyzed proteins. Meta-analysis illustrated that CYP2B6 *1/*6 (OR = 1.83; 95% CI: 1.15-2.90; P = 0.01), *6/*6 (OR = 2.48; 95% CI: 1.28-4.79; P = 0.007), and *1/*6 plus *6/*6 (OR = 1.94; 95% CI: 1.24-3.01; P = 0.003) were associated with risks of EFV-induced liver injury. Moreover, CYP2B6 *1/*6 (OR = 0.44; 95% CI: 0.22-0.91; P = 0.03) and a group combining individuals with either *1/*6 or *6/*6 (OR = 0.42; 95% CI: 0.21-0.84; P = 0.01) were associated with reduced risks of NVP-induced liver injury. This meta-analysis revealed an association between CYP2B6 genetic polymorphism and susceptibility to ARVDILI.

References

Kalyesubula R, Kagimu M, Opio K, Kiguba R, Semitala C, Schlech W . Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci. 2011; 11(1):16-23. PMC: 3092323. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Giacomelli A, Riva A, Falvella F, Oreni M, Cattaneo D, Cheli S . Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect Dis. 2018; 18(1):556. PMC: 6233541. DOI: 10.1186/s12879-018-3462-5. View

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

Nunez M . Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2005; 44(1 Suppl):S132-9. DOI: 10.1016/j.jhep.2005.11.027. View

Blas-Garcia A, Apostolova N, Ballesteros D, Monleon D, Morales J, Rocha M . Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology. 2010; 52(1):115-25. DOI: 10.1002/hep.23647. View

Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K . Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007; 8(6):547-58. DOI: 10.2217/14622416.8.6.547. View

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett J, Lederman M, Maartens G . Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005; 191(6):825-9. DOI: 10.1086/428093. View

Garcia-Blanco D, Gravier-Hernandez R, Rabeiro-Martinez C, Gil Del Valle L, Perez-Avila J . Pharmacogenetic Markers: A Path toward Individualized HIV Therapy. MEDICC Rev. 2019; 21(2-3):59-68. DOI: 10.37757/MR2019.V21.N2-3.11. View

10.

Sharma A, Klarskov K, Uetrecht J . Nevirapine bioactivation and covalent binding in the skin. Chem Res Toxicol. 2013; 26(3):410-21. DOI: 10.1021/tx3004938. View

11.

Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V . Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003; 4(2):115-20. DOI: 10.1310/N4VT-3E9U-4BKN-CRPW. View

12.

Thorn C, Klein T, Altman R . PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol. 2013; 1015:311-20. PMC: 4084821. DOI: 10.1007/978-1-62703-435-7_20. View

13.

Zanger U, Klein K . Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013; 4:24. PMC: 3588594. DOI: 10.3389/fgene.2013.00024. View

14.

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

15.

Ganta K, Mandal A, Chaubey B . Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity. Cell Biol Toxicol. 2016; 33(1):69-82. DOI: 10.1007/s10565-016-9362-9. View

16.

Nikolakopoulou A, Mavridis D, Salanti G . How to interpret meta-analysis models: fixed effect and random effects meta-analyses. Evid Based Ment Health. 2014; 17(2):64. DOI: 10.1136/eb-2014-101794. View

17.

Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J . Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999; 27(8):895-901. View

18.

Chanhom N, Wattanapokayakit S, Satproedprai N, Suvichapanich S, Mahasirimongkol S, Chaikledkaew U . , , and genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients. Heliyon. 2021; 7(4):e06852. PMC: 8082558. DOI: 10.1016/j.heliyon.2021.e06852. View

19.

Jones M, Nunez M . Liver toxicity of antiretroviral drugs. Semin Liver Dis. 2012; 32(2):167-76. DOI: 10.1055/s-0032-1316472. View

20.

Apostolova N, Gomez-Sucerquia L, Moran A, Alvarez A, Blas-Garcia A, Esplugues J . Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol. 2010; 160(8):2069-84. PMC: 2958650. DOI: 10.1111/j.1476-5381.2010.00866.x. View